Literature DB >> 8661988

Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance.

J R Zanchetta1, H Plotkin, E J Roldán.   

Abstract

Long-term treatment with 200 mg dry weight/day of pamidronate (APD) by oral route has been proposed to increase bone mineral density (BMD) in postmenopausal osteoporotic women. However, there is widespread concern over the possibility of bone metabolism "freezing" by protracted use of medication liable to inhibit bone resorption. Accordingly, an open population of 39 osteoporotic women was studied in order to determine BMD variations in lumbar vertebrae and femoral neck and to confirm whether given APD doses increase bone mineralization. A parallel group of osteoporotic women was likewise evaluated to determine the potential reversibility of such effect on discontinuing treatment. Results were beneficial at both skeletal sites in subjects on APD therapy, disclosing at 18 months treatment 9.0% mean peak mineral gain versus basal status at lumbar spine. In the few responders completing 4 years of treatment, mean differences versus basal status were +4.9% in vertebrae and +6.2% at femoral neck. In lumbar vertebrae there was a rapid trend in mineral gain up to 18 months on treatment, which declined thereafter to a quarter of its early rate. Concurrently, in the group of 21 baseline-matched women, effects were evaluated after discontinuing daily APD administration one year (n = 11) or two years (n = 7) later. In both subgroups, there was a loss in lumbar (-7.1% and -9.8% respectively; p<0.01) and femoral neck BMD (-2.2% and -4.2% respectively; p: n.s.) on performing measurement one year after APD withdrawal. Furthermore, after three years treatment and subsequent discontinuance, three patients presented bone loss in lumbar vertebrae and minimal changes at femoral neck one year after APD withdrawal. Therefore, APD induces moderate BMD gain which proves reversible on discontinuing therapy, so that it seems unlikely that this compound should "freeze" bone metabolism to a significant extent. However, the precise degree of such reversibility requires evaluation in larger series.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8661988     DOI: 10.1007/s002239900088

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  15 in total

1.  Bioavailability of enteric-coated sodium fluoride tablets as affected by the administration of calcium supplements at different time intervals.

Authors:  J P Devogelaer; C Nagant de Deuxchaisnes; F Stein
Journal:  J Bone Miner Res       Date:  1990-03       Impact factor: 6.741

Review 2.  The use of bisphosphonates in the treatment of osteoporosis.

Authors:  S E Papapoulos; J O Landman; O L Bijvoet; C W Löwik; R Valkema; E K Pauwels; P Vermeij
Journal:  Bone       Date:  1992       Impact factor: 4.398

3.  Clinical pharmacology of alendronate sodium.

Authors:  B J Gertz; S D Holland; W F Kline; B K Matuszewski; A G Porras
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

4.  Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD.

Authors:  R Valkema; F J Vismans; S E Papapoulos; E K Pauwels; O L Bijvoet
Journal:  Bone Miner       Date:  1989-01

5.  Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate.

Authors:  J O Landman; D H Schweitzer; M Frölich; N A Hamdy; S E Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  1995-02       Impact factor: 5.958

6.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.

Authors:  P M Boonekamp; L J van der Wee-Pals; M M van Wijk-van Lennep; C W Thesing; O L Bijvoet
Journal:  Bone Miner       Date:  1986-02

7.  Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals.

Authors:  F Wingen; D Schmähl
Journal:  Arzneimittelforschung       Date:  1987-09

8.  Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.

Authors:  I R Reid; D J Wattie; M C Evans; G D Gamble; J P Stapleton; J Cornish
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

Review 9.  Diphosphonates: history and mechanisms of action.

Authors:  H Fleisch
Journal:  Metab Bone Dis Relat Res       Date:  1981

10.  Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.

Authors:  M Rossini; D Gatti; N Zamberlan; V Braga; R Dorizzi; S Adami
Journal:  J Bone Miner Res       Date:  1994-11       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.